Menu
Search
|

Menu

Close
X

OvaScience Inc OVAS.OQ (NASDAQ Stock Exchange Global Market)

0.97 USD
-0.00 (-0.27%)
As of Feb 24
chart
Previous Close 0.97
Open 0.97
Volume 5,882
3m Avg Volume 80,779
Today’s High 1.00
Today’s Low 0.95
52 Week High 2.05
52 Week Low 0.91
Shares Outstanding (mil) 35.69
Market Capitalization (mil) 49.96
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
3.00 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
1
FY15
0
EPS (USD)
FY17
-1.190
FY16
-2.593
FY15
-2.703
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
107.44
5.77
Price to Book (MRQ)
vs sector
0.62
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-65.22
14.43
Return on Equity (TTM)
vs sector
-65.89
16.13

EXECUTIVE LEADERSHIP

Christopher Kroeger
Chief Executive Officer, Since 2017
Salary: --
Bonus: --
Jonathan Gillis
principal Financial Officer, principal Accounting Officer, Vice President, Since 2017
Salary: --
Bonus: --
Karen Long
Executive Vice President - Clinical and Regulatory Affairs and Quality Assurance, Since 2016
Salary: --
Bonus: --
James Luterman
Executive Vice President - Research and Development, Since 2016
Salary: --
Bonus: --
Theresa McNeely
Executive Vice President, Chief Communications Officer, Since 2014
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

9 4th Ave
WALTHAM   MA   02451-7506

Phone: +1617.5002802

OvaScience, Inc. is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company's portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient's own ovarian tissue. The Company's AUGMENT treatment is designed to improve egg health by supplementing a mitochondrial deficiency. With the AUGMENT treatment, energy-producing mitochondria from a patient's own EggPC cells are added to the patient's mature eggs during the in vitro fertilization process to supplement the existing mitochondria. Its OvaPrime treatment is a fertility treatment designed to replenish a woman's ovary by increasing her egg reserve using her own EggPC cells. Its OvaTure treatment is a fertility treatment that seeks to create mature fertilizable eggs in vitro from a woman's own EggPC cells without the need for hormone hyperstimulation.

SPONSORED STORIES